ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v11i2.955ppharm-117Research ArticleЛЕКЦИЯLECTUREПРОФИЛАКТИЧЕСКИЕ СТРАТЕГИИ НА ЭТАПАХ ФОРМИРОВАНИЯ И ТЕЧЕНИЯ БРОНХОЛЕГОЧНОЙ ДИСПЛАЗИИPREVENTIVE STRATEGIES IN THE STAGES OF FORMATION AND COURSE OF BRONCHOPULMONARY DYSPLASIAДавыдоваИ. В.DavydovaI. V.

доктор медицинских наук, заведующая Отделом новых технологий изучения особенностей развития ребенкаи амбулаторного контроля за состоянием здоровья НИИ профилактической педиатрии и восстановительного лечения Научного центра здоровья детей

PhD, head of the department of new study technologies of children’s development peculiarities and outpatient health level monitoring at the research institute of preventive pediatrics and medical rehabilitation of the Scientific Center of Children’s Health

davydova@nczd.ruНамазова-БарановаЛ. С.Namazova-BaranovaL. S.ЯцыкГ. В.YatsykG. V.МаянскийН. А.MayanskiyN. A.ЗиминаЕ. П.ZiminaE. P.ОстровскаяА. С.OstrovskayaA. S.Научный центр здоровья детей, МоскваРоссияScientific Center of Children’s Health, MoscowRussian FederationНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская Федерация Российский национальный исследовательский медицинский университет им. Н.И. Пирогова, МоскваРоссияScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Russian Federation Pirogov Russian National Medical Research University, MoscowRussian FederationНаучный центр здоровья детей, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian FederationRussian FederationНаучный центр здоровья детей, Москва, Российская Федерация Первый Московский государственный медицинский университет им. И.М. Сеченова, Российская ФедерацияРоссияScientific Center of Children’s Health, Moscow, Russian Federation Sechenov First Moscow State Medical University, Russian FederationRussian Federation201404042014112Педиатрическая фармакология3440Copyright © Давыдова И.В., Намазова-Баранова Л.С., Яцык Г.В., Маянский Н.А., Зимина Е.П., Островская А.С., 20142014Давыдова И.В., Намазова-Баранова Л.С., Яцык Г.В., Маянский Н.А., Зимина Е.П., Островская А.С.Davydova I.V., Namazova-Baranova L.S., Yatsyk G.V., Mayanskiy N.A., Zimina E.P., Ostrovskaya A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/117

Prevention of development of bronchopulmonary dysplasia (BPD) and possibility of preventing severe course of the disease are the first-priority areas of neonatal pulmonology. Use of modern medical technologies allows protecting a premature infant’s respiratory system from as early as antenatal period of development. Use of the newest neonatal resuscitation protocols may prevent development of BPD. International experience and clinical data gathered by the authors demonstrate that seasonal palivizumab immune prevention of severe course of a respiratory syncytial viral infection in children with BPD results in rarer cases of hospitalization, resuscitation measures and fatal outcomes. The article presents modern preventive strategies used in this category of patients.

 

респираторный дистресс синдромискусственная вентиляция легкихзаместительная терапия сурфактантомбронхолегочная дисплазияреспираторный синцитиальный вируспаливизумабrespiratory distress syndromeartificial pulmonary ventilationsurfactant replacement therapybronchopulmonary dysplasiarespiratory syncytial viruspalivizumabReferencesБаранов А. А., Намазова-Баранова Л. С., Давыдова И. В. Современные подходы к профилактике, диагностике и лечению бронхолегочной дисплазии. Москва: ПедиатрЪ. 2013. С. 8–9.Baranov А. А., Namazova-Baranova L.S., Davydova I.V. Sovremennye podkhody k profilaktike, diagnostike i lecheniyu bronkholegochnoi displazii [Modern Approaches to Prevention, Diagnostics and Treatment of Bronchopulmonary Dysplasia]. Moscow, Pediatr, 2013. pp. 8-9.Намазова-Баранова Л. С., Давыдова И. В., Турти Т. В. Принципы пассивной иммунизации паливизумабом детей из группы риска тяжелого течения РСВ-инфекции. Фарматека. 2013; 1: 51–55.Namazova-Baranova L.S., Davydova I.V., Turti T.V. Farmateka = Paramecia. 2013; 1: 51–55.Баранов А. А., Альбицкий В. Ю. Смертность детского населения России (тенденции, причины и пути снижения). Москва: Союз педиатров России. 2009. С. 342–347.Baranov А.А., Albitskii V.Y. Smertnost' detskogo naseleniya Rossii (tendentsii, prichiny i puti snizheniya) [Pediatric mortality in Russia: tendencies, reasons and means of reducing]. Moscow, Union of Pediatricians of Russia, 2009. pp. 342-347.Давыдова И. В., Мигали А. В., Акоев Ю. С. и др. Возможность благоприятного исхода бронхолегочной дисплазии у ребенка с тяжелым течением заболевания. Справочник педиатра. 2011; 4: 33–39.Davydova I.V., Migali A.V., Akoev Yu.S. etc. Spravochnik pediatra = Pediatrician’s manual. 2011; 4: 33–39.Liggins G. C., Howie R. N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50: 515–525.Liggins G. C., Howie R. N. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972; 50: 515–525.Figueras-Aloy J., Serrano M. M., Rodriguez J. P. et al. Antenatal glucocorticoid treatment decreases mortality and chronic lung disease in survivors among 23-to 28-week gestational age preterm infants. Am J Perinatol. 2005; 22 (8): 441–448.Figueras-Aloy J., Serrano M. M., Rodriguez J. P. et al. Antenatal glucocorticoid treatment decreases mortality and chronic lung disease in survivors among 23-to 28-week gestational age preterm infants. Am. J. Perinatol. 2005; 22 (8): 441–448.Антонов А. Г., Борисевич О. А., Буркова А. С., Ионов О. В., Крючко Д. С., Лёнюшкина А. А., Рындин А. Ю., Филиппов О. С., Чумакова О. В., Терехова Ю. Е. Методическое письмо «Интенсивная терапия и принципы выхаживания детей с экстремально низкой и очень низкой массой тела при рождении». Под ред. д.м.н., профессора Байбариной Е. Н., д.м.н., профессора Дегтярёва Д. Н. Москва. 2011. 72 с.Antonov A.G., Borisevich O.A., Burkova A.S., Ionov O.V., Kryuchko D.S., Lenyushkina A.A., Ryndin A.Yu., Filippov O.S., Chumakova O.V., Terekhova Yu.E. Metodicheskoe pis'mo «Intensiv naya terapiya i printsipy vykhazhivaniya detei s ekstremal'no nizkoi i ochen' nizkoi massoi tela pri rozhdenii». Pod red. d.m.n., professora Baibarinoi E.N., d.m.n., professora Degtyareva D.N. [Methodological Letter “Intensive Therapy and Principles of Developmental Care of Infants with Extremely Low or Very Low Birth Weight”. Edited by PhD, Professor E.N. Baibarina and PhD, Professor D.N. Degtyarev]. Moscow, 2011. 72 p.Kribs A. et al. Surfactant without Intubation in Preterm Infants with Respiratory Distress: First Multi-center Data. Сlin Paеdiatr. 2010; 222: 13–17.Kribs A. et al. Surfactant without Intubation in Preterm Infants with Respiratory Distress: First Multi-center Data. Сlin. Paеdiatr. 2010; 222: 13–17.Singh N., Hawley K. L., Viswanathan K. Efficacy of Pocine Versus Bovine Surfactant for Preterm Newborns With Respiratory Distress Syndrome: Review and Meta-analysis. Pediatrics. 2001; 128: 1588–1595.Singh N., Hawley K. L., Viswanathan K. Efficacy of Pocine Versus Bovine Surfactant for Preterm Newborns With Respiratory Distress Syndrome: Review and Meta-analysis. Pediatrics. 2001; 128: 1588–1595.Engle W. A. Committee on Fetus and Newborn: Surfactant Replaycement Therapy for Respiratory Distress in the Preterm and Term Neonate. Pediatrics. 2008; 121: 419–432.Engle W.A. Committee on Fetus and Newborn: Surfactant Replaycement Therapy for Respiratory Distress in the Preterm and Term Neonate. Pediatrics. 2008; 121: 419–432.Володин Н. Н., Байбарина Е. Н. Протокол ведения недоношенных детей с гемодинамически значимым функционирующим артериальным протоком. Москва. 2010. 34 с.Volodin N.N., Baybarina E.N. Protokol vedeniya nedonoshennykh detei s gemodinamicheski znachimym funktsioniruyushchim arterial'nym protokom [Management Protocol for Premature Infants with Hemodynamically Significant Functioning Arterial Duct]. Moscow, 2010. 34 p.Halliday H. L., Ehrenkranz R. A., Doyle L. W. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2009. CD001145.Halliday H. L., Ehrenkranz R. A., Doyle L. W. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. 2009. CD001145.Henderson-Smart D. J., Steer P. A. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews. 2010. CD000273.Henderson-Smart D. J., Steer P. A. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database of Systematic Reviews. 2010. CD000273.Stewart A., Brion L. P. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2011. CD001453.Stewart A., Brion L. P. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2011. CD001453.Stewart A., Brion L. P., Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2011. CD001817.Stewart A., Brion L. P., Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database of Systematic Reviews. 2011. CD001817.Tyson J. E., Wright L. L., Oh W. et al. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999; 340: 1962–1968.Tyson J. E., Wright L. L., Oh W. et al. Vitamin A supplementation for extremely-low-birth-weight infants. N. Engl. J. Med. 1999; 340: 1962–1968.Merrill J. D., Ballard R. A., Cnaan A. et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr Res. 2004; 56: 1–9.Merrill J. D., Ballard R. A., Cnaan A. et al. Dysfunction of pulmonary surfactant in chronically ventilated premature infants. Pediatr. Res. 2004; 56: 1–9.Thomas W., Speer C. O. Bronchopulmonale Dysplasie Fruehge-borener Epidemiologie, Pathogenese und Therapie. Monatsschrift Kinderheilkd. 2005; 153: 211–219.Thomas W., Speer C. O. Bronchopulmonale Dysplasie Fruehgeborener Epidemiologie, Pathogenese und Therapie. Monatsschrift Kinderheilkd. 2005; 153: 211–219.Laughon M., Bose C., Moya F., Aschner J. et al. A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia. Pediatrics. 2009; 123 (1): 89–96.Laughon M., Bose C., Moya F., Aschner J. et al. A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia. Pediatrics. 2009; 123 (1): 89–96.Рындин А. Ю., Антонов А. Г. Патент RU 2416388 C1 «Способ профилактики бронхолегочной дисплазии у новорожденных с очень низкой и экстремально низкой массой тела при рождении». Бюлл. № 11. Дата публикации: 20.04.2011.Ryndin A.Y., Antonov A.G. Patent RU 2416388 C1 «Sposob profilaktiki bronkholegochnoi displazii u novorozhdennykh s ochen' nizkoi i ekstremal'no nizkoi massoi tela pri rozhdenii». Byull. № 11 [Patent No. RU 2416388 C1 “Method of preventing bronchopulmonary dysplasia in neonates with very low or extremely low birth weight”. Bulletin. No. 11]. Moscow, 2011.Northway W.H.Jr., Rosan R. C., Porter D. Y. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967; 276: 357–368.Northway W.H.Jr., Rosan R. C., Porter D. Y. Pulmonary disease following respiratory therapy of hyaline-membrane disease. Bronch opulmonary dysplasia. N. Engl. J. Med. 1967; 276: 357–368.Simoes E. A. F. Respiratory syncytial virus infection. Lancet. 1999; 354 (9181): 847–852.Simoes E. A. F. Respiratory syncytial virus infection. Lancet. 1999; 354 (9181): 847–852.Островская А. С., Давыдова И. В., Лазарева А. В., Маянский Н. А. Оценка вирусно-микробного пейзажа носоглотки у детей с бронхолегочной дисплазией вне обострения заболевания. Материалы XVII Конгресса педиатров России с международным участием «Актуальные проблемы педиатрии». Москва. 2014. С. 247.Ostrovskaya A.S., Davydova I.V., Lazareva A.V., Mayanskii N.A. Otsenka virusno-mikrobnogo peizazha nosoglotki u detei s bronkholegochnoi displaziei vne obostreniya zabolevaniya. [Evaluation of nasopharyngeal viromicrboial flora in children with non-acute bronchopulmonary dysplasia]. Materialy XVII Kongressa pediatrov Rossii s mezhdunarodnym uchastiem «Aktual'nye problemy pediatrii» (Proceedings of the XVII International Congress of Pediatricians of Russia “Relevant Issues of Pediatrics”). Moscow, 2014. p. 247.Garenne M., Ronsmans C., Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q. 1992; 45 (2–3): 180–191.Garenne M., Ronsmans C., Campbell H. The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries. World Health Stat Q. 1992; 45 (2–3): 180–191.Colin A. M., McEnvoy C., Castile R. Respiratory morbidity and lung function in preterm infants 32–36 weeks gestational age. Pediatrics. 2010. DOI: 10.1542/peds.2009. P. 1381.Colin A. M., McEnvoy C., Castile R. Respiratory morbidity and lung function in preterm infants 32–36 weeks gestational age. Pediatrics. 2010. DOI: 10.1542/peds.2009. P. 1381.Boyce T. G., Mellen B. G., Mitchel E. F. et al. Rates of hospitalization for respiratory syncytial virus among children in Medicaid. J Pediatr. 2000; 137: 865–870.Boyce T. G., Mellen B. G., Mitchel E. F. et al. Rates of hospitalization for respiratory syncytial virus among children in Medicaid. J. Pediatr. 2000; 137: 865–870.Horn S. D., Smout R. J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr. 2003; 143: 133–141.Horn S. D., Smout R. J. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J. Pediatr. 2003; 143: 133–141.Баранов А. А., Давыдова И. В., Намазова-Баранова Л. С. и др. Иммунопрофилактика тяжелого течения респираторно-синтициальной вирусной инфекции у детей с бронхолегочной дисплазией: результаты четырех эпидемических сезонов. Педиатрическая фармакология. 2012; 9 (6): 48–53.Baranov A.A., Davydova I.V., Namazova-Baranova L.S. etc. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 9(6): 48–53.Navas G. et al. Improved outcome of RSV infection in a high-risk hospitalized population of Canadian children. J Pediatr. 1992; 121: 348–354.Navas G. et al. Improved outcome of RSV infection in a highrisk hospitalized population of Canadian children. J. Pediatr.1992; 121: 348–354.Давыдова И. В., Яцык Г. В., Тресорукова О. В. и др. Клинико-функциональные особенности течения бронхолегочной дисплазии в первом полугодии жизни. Российский педиатрический журнал. 2008; 6: 10–13.Davydova I.V., Yatsyk G.V., Tresorukova O.V. etc. Rossiiskii pediatricheskii zhurnal = Russian pediatric journal. 2008; 6: 10–13.Glezen W. P., Taber L. H., Frank A. L. et al. Rick of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986; 140 (6): 543–546.Glezen W. P., Taber L. H., Frank A. L. et al. Rick of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986; 140 (6): 543–546.Everard M. Diagnosis, admission, discharge. Paediatr Respir Rev. 2009; 10 (Suppl. 1): 18–20.Everard M. Diagnosis, admission, discharge. Paediatr. Respir. Rev. 2009; 10 (Suppl. 1): 18–20.Wellier R. C., Chechia P. A., Bauman J.H. et al. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Cu Med Res Opin. 2010; 29 (9): 2175–2181.Wellier R. C., Chechia P. A., Bauman J.H. et al. Fatality rates in published reports of RSV hospitalizations among highrisk and otherwise healthy children. Cu Med. Res. Opin. 2010; 29(9): 2175–2181.Prince G. A., Jenson A. B., Hemming V. G. et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by intramuscular inoculation of formalin-inactivated virus. Journal of Virology. 1986; 57: 721–728.Prince G. A., Jenson A. B., Hemming V. G. et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by intramuscular inoculation of formalin-inactivated virus. Journal of Virology. 1986; 57: 721–728.Синагис (инструкция по применению). Эбботт Лэбораториз С. А.Sinagis (instruktsiya po primeneniyu) [Synagis: Application; the Abbott Laboratories].Таточенко В. К. Вакцинация недоношенных и маловесных детей. Педиатрическая фармакология. 2013; 10 (4): 30–37.Tatochenko V.K. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10(4): 30–37.

The authors declare that there are no conflicts of interest present.